LAPIX Therapeutics Appoints Nimbus CEO Abbas Kazimi to Board of Directors
AI Briefing
- • LAPIX Therapeutics appoints Abbas Kazimi, Nimbus CEO, to its Board of Directors.
- • Kazimi brings over two decades of biotech leadership experience to the new role.
- • He will oversee LAPIX's TIM 3/4 agonist program in Phase 1b clinical trials for RA and AD.
Context
LAPIX Therapeutics has appointed Abbas Kazimi to its Board of Directors. Kazimi is the Chief Executive Officer of Nimbus Therapeutics. He brings over two decades of biotechnology leadership experience to the board.
Kazimi's experience spans company building, corporate strategy, financing, and drug development. His appointment comes as LAPIX Therapeutics advances its TIM 3/4 agonist program through Phase 1b clinical trials in rheumatoid arthritis and atopic dermatitis.
Advertisement